Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans--two case reports.
Thromboangiitis obliterans (TAO) is a nonatherosclerotic, nonnecrotizing, nonspecific, segmental inflammatory obliterative vasculitis, characterized by decreased flow to the distal extremities and increased risk of amputation. While smoking cessation is viewed as critical to successful treatment, various therapeutic options have been employed. While many treatment regimens seek to diminish platelet function, there are relatively few studies of platelet function in this disease entity and even fewer that have offered evidence of increased platelet activity. The authors report here 2 cases of TAO in which evaluations for hypercoagulable states and of platelet function were performed. Platelet contractile force (PCF) was found to be 82% higher than a normal control in 1 TAO patient and 340% higher than normal in the second patient. This was true despite the fact that platelet aggregations confirmed suppression of aggregation by antiplatelet medications. Elevated PCF has been seen in a variety of conditions, such as coronary artery disease and diabetes mellitus, in which endothelial function is abnormal. Whether high PCF values play a role in the pathogenesis of these diseases or simply serve as markers of enhanced platelet function and/or endothelial dysfunction awaits additional evaluations.
Carr
Marcus E
ME
Departments of Medicine and Pathology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0230, USA. mcarr@hsc.vcu.edu
Hackney
Mary H
MH
Hines
Susan J
SJ
Heddinger
Steven P
SP
Carr
Sheryl L
SL
Martin
Erika J
EJ
D000328:Adult; D001792:Blood Platelets / Q000502:physiology*; D003018:Clot Retraction; D004548:Elasticity; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D012907:Smoking / Q000009:adverse effects; D013919:Thromboangiitis Obliterans / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors